Adeno-associated virus affinity purification centrifugal column

By designing adeno-associated virus affinity purification spin column, using affinity filler and filtration device of single-domain antibodies, the problem of low purification efficiency of adeno-associated viruses is solved, and efficient and simple purification of adeno-associated viruses is achieved, suitable for research and development and production Quick quality inspection.

CN119040280APending Publication Date: 2024-11-29SHANGHAI YAONUO BIOTECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411155372.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-08-08
Filing Date
2024-08-22
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The purification efficiency of adeno-associated viruses in the prior art is low, and there are equipment limitations and process complexity problems in R&D and industrial production, making it difficult to quickly obtain high-purity adeno-associated viruses.

Method used

A penis column with affinity purification of adeno-associated virus was designed, using affinity filler containing single domain antibodies, combined with upper and lower filtration devices, simplifying the purification process of adeno-associated viruses, and effectively purifying AAV2, AAV5 and AAV8 without An ultracentrifuge and protein purification device are required.

Benefits of technology

It realizes efficient purification of adeno-associated viruses, simplifies the operation process, significantly reduces experimental time and cost, and is suitable for rapid quality inspection in R&D and production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040280A_ABST
    Figure CN119040280A_ABST
Patent Text Reader

Abstract

The adeno-associated virus affinity purification centrifugal column comprises a sample inner tube and a filtrate collecting tube arranged outside the sample inner tube in a sleeving manner, an affinity filler filling section is arranged at the lower part of the sample inner tube, an upper-layer filtering device is arranged on the upper side of the affinity filler filling section, a lower-layer filtering device is arranged on the lower side of the affinity filler filling section, the affinity filler contains single-domain antibodies, and the single-domain antibodies comprise CDR1, CDR2 and CDR3; the adeno-associated virus affinity purification centrifugal column can effectively purify AAV2, AAV5 and AAV8, the operation of the centrifugal column is simple, a user only needs to carry out simple coarse treatment on adeno-associated viruses to obtain the adeno-associated viruses meeting centrifugal purification conditions, purification can be completed without cooperation with an ultra-speed centrifuge and a protein purification instrument, and the cost is low. And the experiment time and cost are greatly reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of centrifugal columns, in particular to an adeno-associated virus affinity purification centrifugal column. Background Art

[0002] Adeno-associated virus has the advantages of long-term expression, low toxicity, low immunogenicity and high tissue specificity, so it has gradually become one of the most important gene vectors in the field of gene therapy and has been widely used. There are now many ways to purify adeno-associated virus. Among them, cesium chloride (CsCl) / iodixanol density gradient centrifugation is the most traditional AAV purification technology. This technology is applicable to all serotypes and has high resolution. However, due to the difficulty of amplifying the production process, low throughput and the need for ultracentrifuges, it hinders the rapid acquisition of purified adeno-associated virus in research and development and large-scale amplification in industrial production. In addition, cesium chloride (CsCl) and iodixanol need to be controlled and detected in the final product, which also increases the difficulty of research and development and the process challenges in subsequent production to a certain extent. Secondly, ion exchange chromatography is also one of the most widely used purification methods, but it is more demanding on process exploration, and there are large differences between batches. The connection requirements of upstream and downstream processes are high. Most of them are refined solutions adopted after one-step affinity purification of adeno-associated virus. Then, affinity fillers must be mentioned for the purification of adeno-associated viruses, because of their high purification efficiency, and one-time purification can effectively reduce impurities; they can be used for large-scale AAV purification when combined with AKTA equipment. However, in research and development work, how to quickly and conveniently obtain adeno-associated viruses with higher purity is a challenge. This patent discloses a convenient centrifugal column that can affinity purify adeno-associated viruses of various serotypes. It can complete small-scale purification of adeno-associated viruses by adapting to different centrifugal columns, and is used for rapid quality inspection for research and development use and production, filling the gap in the use of centrifugal columns for the purification of adeno-associated viruses in the domestic and foreign markets. Summary of the invention

[0003] The technical problem to be solved by the present invention is: in order to solve the problem of low purification efficiency of adeno-associated virus in the prior art, the present invention provides an adeno-associated virus affinity purification centrifugal column.

[0004] The technical solution adopted by the present invention to solve the technical problem is: an adeno-associated virus affinity purification centrifugal column, comprising a sample inner tube and a filtrate collection tube sleeved on the outside of the sample inner tube; an affinity filler filling section is provided at the lower part of the sample inner tube, an upper filter device is provided on the upper side of the affinity filler filling section, and a lower filter device is provided on the lower side, the affinity filler contains a single domain antibody, and the single domain antibody includes CDR1, CDR2, and CDR3,

[0005] The amino acid sequence of the CDR1 is as shown in SEQ ID NO: 2, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity;

[0006] The amino acid sequence of the CDR2 is as shown in SEQ ID NO: 3, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity;

[0007] The amino acid sequence of the CDR3 is shown in SEQ ID NO: 4, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity.

[0008] Furthermore, the upper filter device includes an upper clamp ring, an upper filter disc and an upper mesh plastic gasket arranged in sequence from top to bottom; the lower filter device includes a lower clamp ring, a lower filter disc and a lower mesh plastic gasket arranged in sequence from top to bottom.

[0009] Furthermore, the pore size of the filter disc of the upper layer is 0.3-0.8 micron; the pore size of the filter disc of the lower layer is 0.3-0.8 micron; preferably, the pore size of the filter disc of the upper layer is 0.5 micron, and the pore size of the filter disc of the lower layer is 0.5 micron.

[0010] Furthermore, a liquid outlet is provided at the bottom of the sample inner tube, and a clamping portion for clamping with the filtrate collecting tube is provided at the upper portion of the sample inner tube, and the outer diameter of the clamping portion is the same as the inner diameter of the filtrate collecting tube.

[0011] Furthermore, a leak-proof cover is connected to the top of the sample inner tube for sealing the sample inner tube, and the leak-proof cover includes a connecting portion connected to the sample inner tube, an opening and closing portion for facilitating opening or closing of the cover body, and a sealing portion for plugging the sample inner tube to prevent the sample from flowing out during centrifugation; the sealing portion is a columnar structure, and the outer diameter of the sealing portion matches the inner diameter of the upper portion of the sample inner tube.

[0012] Furthermore, a threaded opening is provided on the top outer ring of the filtrate collecting tube, and the threaded opening is connected to a threaded cover.

[0013] Furthermore, the mutant may be the following:

[0014] The amino acid sequence of the CDR1 is shown in SEQ ID NO: 21; the amino acid sequence of the variable region is shown in SEQ ID NO: 35;

[0015] The amino acid sequence of the CDR2 is shown in SEQ ID NO:30; the amino acid sequence of the variable region is shown in SEQ ID NO:43;

[0016] The amino acid sequence of the CDR3 is shown in SEQ ID NO:39; the amino acid sequence of the variable region is shown in SEQ ID NO:51;

[0017] The amino acid sequence of the CDR1 is shown as SEQ ID NO:45, the amino acid sequence of the CDR1 is shown as SEQ ID NO:46; the amino acid sequence of the CDR1 is shown as SEQ ID NO:47; at this time, the amino acid sequence of the variable region is shown as SEQ ID NO:44.

[0018] Furthermore, the single-domain antibody also includes a framework region FR1 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:5.

[0019] Furthermore, the single-domain antibody also includes a framework region FR2 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:6.

[0020] Furthermore, the single-domain antibody also includes a framework region FR3 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:7.

[0021] Furthermore, the single-domain antibody also includes a framework region FR4 that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:8.

[0022] Furthermore, the amino acid sequence of the single domain antibody is shown in SEQ ID NO.1.

[0023] Another aspect of the present invention provides a gene encoding the above-mentioned single domain antibody.

[0024] Furthermore, the nucleotide sequence of the gene is shown in SEQ ID NO.16.

[0025] Another aspect of the present invention provides a vector, wherein the vector contains or has the above gene inserted therein.

[0026] Furthermore, the vector may be pET-22b(+).

[0027] Another aspect of the present invention provides a cell, wherein the cell contains the above-mentioned vector.

[0028] Furthermore, the cell may be Escherichia coli.

[0029] Another aspect of the present invention provides the use of the single domain antibody for purifying AAV. The AAV can be a common species, such as AAV2, AAV5, AAV6 and AAV8.

[0030] Another aspect of the present invention provides a filler for purifying AAV, wherein the filler contains the above-mentioned single domain antibody. The product may be a resin filler.

[0031] Further, the single domain antibody is coupled to a microsphere. The microsphere can be a microsphere made of agarose gel. Such microspheres can usually be used for affinity purification of AVV. Those skilled in the art can purchase them from the market.

[0032] Beneficial effects of the present invention:

[0033] The adeno-associated virus affinity purification centrifugal column described in the present invention can effectively purify AAV2, AAV5 and AAV8, and the centrifugal column is easy to operate. The user only needs to perform simple rough treatment on the adeno-associated virus to obtain conditions that meet the centrifugal purification, and purification can be completed without the use of an ultracentrifuge and a protein purifier, which greatly reduces experimental time and cost. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The present invention is further described below in conjunction with the accompanying drawings and embodiments.

[0035] Figure 1 Schematic diagram of the adeno-associated virus affinity purification spin column described in Example 1 of the present invention;

[0036] Figure 2 This is a schematic diagram of the sample inner tube described in Example 1 of the present invention;

[0037] Figure 3 Schematic diagram of the adeno-associated virus affinity purification spin column described in Example 2 of the present invention;

[0038] Figure 4 This is a schematic diagram of the filtrate collecting tube described in Example 2 of the present invention;

[0039] Figure 5 Agarose gel electrophoresis of PCR amplification of inserted gene. Lane M: DNA Marker; Lane 1-2: PCR amplification product.

[0040] Figure 6 Agarose gel electrophoresis of bacterial liquid PCR identification. Lane M: DNA Marker; Lanes 1-8: PCR amplification products of bacterial liquid.

[0041] Figure 7 Agarose gel electrophoresis of empty vector digestion. Lane M: DNA Marker; Lane 1: pET-22b(+) empty vector digestion product.

[0042] Figure 8Agarose gel electrophoresis of recombinant plasmid digestion. Lane M: DNA Marker; Lane 1: pET-22b(+) plasmid; Lane 2: ApaI-XhoI digestion product of pET-22b(+).

[0043] Fig. 9 Map of the pET-22b(+) plasmid with the single domain antibody gene sequence inserted.

[0044] Fig.10 Sequencing results of pET-22b(+) plasmid with inserted single domain antibody gene sequence.

[0045] Fig.11 Gel electrophoresis diagram of expression identification results. Lane M: protein marker; Lane 1: uninduced sample; Lanes 2-6: induced samples.

[0046] Fig.12 Gel electrophoresis plots of optimization and solubility analysis results. Lane M: protein marker; Lane 1: sample induced by 0.2mM IPTG at 15℃; Lane 2: sample induced by 1.0mM IPTG at 15℃; Lane 3: sample induced by 0.2mM IPTG at 37℃; Lane 4: sample induced by 1.0mM IPTG at 37℃; Lane 5: uninduced sample; Lane 6: precipitate sample induced by 1.0mM IPTG at 37℃; Lane 7: supernatant sample induced by 1.0mM IPTG at 37℃; Lane 8: precipitate sample induced by 0.2mM IPTG at 37℃; Lane 9: supernatant sample induced by 0.2mM IPTG at 37℃; Lane 10: precipitate sample induced by 1.0mM IPTG at 15℃; Lane 11: supernatant sample induced by 1.0mM IPTG at 15℃; Lane 12: precipitate sample induced by 0.2mM IPTG at 15℃; Lane 13: precipitate sample induced by 0.2mM IPTG at 15℃ Supernatant sample after IPTG induction.

[0047] Fig.13 Affinity purification SDS-PAGE results. Lane M: protein marker; Lane 1: precipitate after fragmentation; Lane 2: supernatant after fragmentation; Lane 3: effluent; Lane 4: washing sample; Lane 5: elution sample.

[0048] Fig.14 Protein dialysis SDS-PAGE results. Lane M: protein marker; Lane S: dialyzed sample.

[0049] Fig.15 Protein purification SDS-PAGE results. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0050] Fig.16 . Analysis curve of single domain antibody binding activity to AAV2 ELISA.

[0051] Fig.17 .Analysis curve of single domain antibody binding activity to AAV5 ELISA.

[0052] Fig.18 . Analysis curve of single domain antibody binding activity to AAV6 ELISA.

[0053] Fig.19 .Analysis curve of single domain antibody binding activity to AAV8 ELISA.

[0054] Fig. 20 . Analysis curve of single domain antibody binding activity to AAV2 ELISA.

[0055] Fig.21 .Analysis curve of single domain antibody binding activity to AAV5 ELISA.

[0056] Fig. 22 . Analysis curve of single domain antibody binding activity to AAV6 ELISA.

[0057] Fig.23 .Analysis curve of single domain antibody binding activity to AAV8 ELISA.

[0058] Fig.24 .Affinity purification chromatogram of AAV5 dynamic loading using single domain antibody affinity medium.

[0059] Fig.25 .Silver staining detection after affinity purification of AAV2 dynamic loading by single domain antibody affinity filler. Lane 1: protein marker; Lane 2: AAV2 crude extract; Lane 3: flow-through; Lane 4: eluate; Lane 5: protein marker

[0060] Fig.26 Silver staining detection after affinity purification of AAV5 dynamic loading by single domain antibody affinity filler. Lane 1: protein marker; Lane 2: AAV5 crude extract; Lane 3: flow-through; Lane 4: eluate; Lane 5: protein marker.

[0061] Fig. 27 Silver staining detection after affinity purification of AAV8 dynamic loading by single domain antibody affinity filler. Lane 1: protein marker; Lane 2: AAV8 crude extract; Lane 3: flow-through; Lane 4: eluate; Lane 5: marker.

[0062] Fig.28 . SDS-PAGE results of G30A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0063] Fig.29. SDS-PAGE results of S56T protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0064] Fig.30 . SDS-PAGE results of G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0065] Fig.31 . SDS-PAGE results of G30A / S56T / G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0066] Fig.32 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV2 ELISA.

[0067] Fig.33 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV5 ELISA.

[0068] Fig.34 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV6 ELISA.

[0069] Fig.35 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV8 ELISA.

[0070] In the figure, 1, sample inner tube, 2, filtrate collecting tube, 3, affinity filler filling section, 4, upper filtering device, 41, upper clamping ring, 42, upper filter disc, 43, upper mesh plastic gasket, 5, lower filtering device, 51, lower clamping ring, 52, lower filter disc, 53, lower mesh plastic gasket, 6, liquid outlet, 7, clamping part, 8, leak-proof cover, 81, connecting part, 82, opening and closing part, 83, sealing part, 9, threaded mouth, 10, threaded cover. DETAILED DESCRIPTION

[0071] The term "single domain antibody" has the ordinary meaning in the art and refers to a single heavy chain variable domain of an antibody type that can be found in camelid mammals that is naturally free of light chains. The amino acid sequence and structure of a single domain antibody can be considered to consist of four framework regions or "FRs", which are referred to in the prior art and herein as "framework region 1" or "FR1"; "framework region 2" or "FR2"; "framework region 3" or "FR3"; "framework region 4" or "FR4", respectively, and the framework regions are separated by three complementary determining regions or "CDRs", which are referred to in the prior art as "complementary determining region 1" or "CDR1"; "complementary determining region 2" or "CDR2" and "complementary determining region 3" or "CDR3". Therefore, a single domain antibody can be defined as an amino acid sequence having the following general structure: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, wherein FR1 to FR4 refer to framework regions 1-4, respectively, and CDR1 to CDR3 refer to complementary determining regions 1-3, respectively. In the context of the present invention, the amino acid residues of a single domain antibody are numbered according to the general code of the VH domain given by the IMGT numbering system. The results of the kabat rule numbering are also shown below. However, in order to avoid ambiguity, the IMGT numbering system is mainly used herein.

[0072] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and cannot be understood as limiting the present invention.

[0073] In the description of the present invention, it is necessary to understand that the terms "upper", "lower", "horizontal", "top", "inside", etc. indicate orientations or positional relationships based on the orientations or positional relationships shown in the accompanying drawings, and are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as a limitation on the present invention.

[0074] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the term "connection" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0075] Example 1

[0076] like Figure 1-2As shown, an adeno-associated virus affinity purification centrifugal column comprises a sample inner tube 1 and a filtrate collecting tube 2 which is sleeved on the outside of the sample inner tube 1; an affinity filler filling section 3 is provided at the lower part of the sample inner tube 1, an upper layer filtering device 4 is provided on the upper side of the affinity filler filling section 3, and a lower layer filtering device 5 is provided on the lower side.

[0077] The upper filter device 4 includes an upper clamp ring 41, an upper filter disc 42 and an upper mesh plastic gasket 43 arranged in sequence from top to bottom; the lower filter device 5 includes a lower clamp ring 51, a lower filter disc 52 and a lower mesh plastic gasket 53 arranged in sequence from top to bottom. The filter pores of the upper filter disc 42 have an aperture of 0.5 microns; the filter pores of the lower filter disc 52 have an aperture of 0.5 microns.

[0078] The bottom of the sample inner tube 1 is provided with a liquid outlet 6 , and the upper part of the sample inner tube 1 is provided with a clamping portion 7 clamped with the filtrate collecting tube 2 , and the outer diameter of the clamping portion 7 is the same as the inner diameter of the filtrate collecting tube 2 .

[0079] The top of the sample inner tube 1 is connected with a leak-proof cover 8 for sealing the sample inner tube 1. The leak-proof cover 8 includes a connecting portion 81 connected to the sample inner tube 1, an opening and closing portion 82 for opening or closing the cover body, and a sealing portion 83 for plugging the sample inner tube 1 to prevent the sample from flowing out during centrifugation; the sealing portion 83 is a columnar structure, and the outer diameter of the sealing portion 83 matches the inner diameter of the upper portion of the sample inner tube 1.

[0080] When in use, first plug the lower gasket, lower filter disc 52 and lower retaining ring 51 of the lower half of the sample inner tube 1, add 50ul of affinity purification filler, and then fill the upper gasket, upper filter disc 42 and upper retaining ring 41 of the upper half after the filler settles under the action of gravity; then put the filtrate collection tube 2 on the outside of the sample inner tube 1, and then close the lid to complete the assembly of the centrifugal column.

[0081] Example 2

[0082] This embodiment further provides an adeno-associated virus affinity purification spin column based on embodiment 1, and its structure is substantially the same as that of the adeno-associated virus affinity purification spin column described in embodiment 1, except that: Figure 3-4 As shown, a threaded opening 9 is provided on the top outer ring of the filtrate collecting tube 2 , and the threaded opening 9 is connected to a threaded cover 10 .

[0083] Example 3 Single domain antibody variable region sequence

[0084] 3. Single domain antibody variable region sequence:

[0085] QVQLQESGGGLVQAGGSLRLSCAASGRTHGMYAMGWFRQAPGKEREFVAVQDLTASNTHYSSAVKGRFTISSRDNAK NTAYLQMNNLKPEDTAVYYCAAGPTIMSGSYNSARDYDYWGQGTQVTVSS(SEQ ID NO.1)

[0086] 3.1 IMGT Rule Number

[0087] The CDR1 sequence is GRTHGMYA (SEQ ID NO. 2)

[0088] The CDR2 sequence is QDLTASNT (SEQ ID NO. 3)

[0089] The CDR3 sequence is AAGPTIMSGSYNSARDYDY (SEQ ID NO. 4)

[0090] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 5)

[0091] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO.6)

[0092] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO.7)

[0093] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.8)

[0094] 3.2 Kabat rule number

[0095] The CDR1 sequence is MYAMG (SEQ ID NO.9)

[0096] The CDR2 sequence is VQDLTASNTHYSSAVKG (SEQ ID NO. 10)

[0097] The CDR3 sequence is GPTIMSGSYNSARDYDY (SEQ ID NO. 11)

[0098] FR1 sequence is QVQLQESGGGLVQAGGSLRLSCAASGRTHG (SEQ ID NO. 12)

[0099] FR2 sequence is WFRQAPGKEREFVA (SEQ ID NO. 13)

[0100] FR3 sequence is RFTISRDNAKNTAYLQMNNLKPEDTAVYYCAA (SEQ ID NO. 14)

[0101] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.15)

[0102] Example 4 Expression and purification of single domain antibodies in E. coli

[0103] We expressed the screened single domain antibodies in eukaryotic and prokaryotic systems and then purified them.

[0104] 4.1 Plasmid construction, transformation and identification

[0105] 4.1.1 Plasmid construction

[0106] The nucleotide sequence of the target gene is as follows (SEQ ID NO.16):

[0107] CAGGTGCAGCTGCAGGAAAGCGGCGGTGGTCTGGTTCAGGCAGGTGGTAGTCTGCGCCTGAGTTTGCCGCAAGTGGCCGTACCCATGGTATGTATGCAATGGGTTGGTTTCGTCAGGCACCGGGTAAAGAACGCGAATTTGTGGCCGTGCAGGATCTGACCGCCAGCAATACCCATTATAGCAGTGCCGTGAAAGG TCGCTTTACCATTAGTCGTGATAATGCCAAAAATACCGCCTATCTGCAGATGAATAATCTGAAACCGGAAGATACCGCCGTTTATTATTGCGCAGCCGGCCCGACCATTATGAGCGGTAGTTATAATAGCGCACGTGATTATGATTATTGGGGCCAGGGTACCCAGGTTACCGTTAGTAGCGCAGCCCCGGGCTGC.

[0108] The primers of the single-domain antibody target gene sequence were amplified by PCR to obtain a fragment PCR product, which was recombined into the target vector pET-22b(+) (NdeI, XhoI restriction enzyme vector) by a multi-segment recombination method to obtain a full-length construct. The connection method is as follows.

[0109] The processed target fragment and vector connection reaction system

[0110]

[0111]

[0112] 4.1.2 Plasmid transformation

[0113] a. Add 1 μl of plasmid to 100 μl of competent cells, gently shake and rotate to mix, and place on ice for 3 minutes;

[0114] b. 42℃ water bath for 90s;

[0115] c. Place in ice bath for 3 minutes;

[0116] d. Add 800 μl of 37°C pre-warmed LB medium to each tube and shake gently at 200 rpm at 37°C for 40 minutes.

[0117] 4.1.3 Verification of recombinants

[0118] a. Prepare agar plates containing corresponding resistance;

[0119] b. Take 100 μl of bacterial solution and add it to the agar plate containing the corresponding resistance. Use a sterile glass applicator to gently spread the bacteria on the surface of the plate and incubate the plate at 37°C for 15 minutes.

[0120] c. Invert the plate and incubate at 37°C for 12-16 hours;

[0121] d. Pick bacteria from the plate and shake at 37℃ and 250 rpm for 14 hours. Perform PCR identification on the bacterial solution and send the positive clone solution for sequencing.

[0122] 4.1.4 Verification of cloned plasmids

[0123] Upstream primer:

[0124] AATTTTGTTTAACTTTAAGAAGGAGATATACATATGCATCATCATCACCATCAGGT TCAG(SEQID NO.17)

[0125] Downstream primer:

[0126] AGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAGTTAACAACCCGGGGCTGCACTACTCACGGTCACCT(SEQ ID NO.18)

[0127] a. PCR reaction uses a 50μL system: 2μL of primers, 2μL of template, 10μL of polymerase buffer, 1μL of 10MmdNTP, 1μL of polymerase, 32μL of ddH2O. Cycle parameters: 96℃ pre-denaturation for 5min; 95℃ for 15S, 58℃ for 15S, 72℃ for about 30s, 23 cycles, and final extension at 72℃ for 1min;

[0128] b. Screen positive clones by bacterial solution PCR method, extract plasmids from the obtained positive bacterial solution at 37℃ and send them for sequencing;

[0129] c. Sequence the correct plasmid and perform double restriction digestion with ApaI-XhoI.

[0130] 4.1.5 Plasmid construction results

[0131] a. After PCR amplification of the single domain antibody target gene sequence, agarose gel electrophoresis was performed. The amplification results of the sample were as follows: Figure 5 .

[0132] b. Genetic bacterial liquid identification, after PCR amplification, agarose gel electrophoresis was performed, and the amplification results of the samples were as follows Figure 6 .

[0133] c. Empty vector digestion results: pET-22b(+) empty vector digestion was performed and then subjected to agarose gel electrophoresis. The results are as follows: Figure 7 .

[0134] d. Identification of recombinant cloned plasmids: The target gene obtained by PCR amplification was constructed into the pET-22b(+) vector, the plasmid was extracted, and the plasmid was digested with ApaI-XhoI and then subjected to agarose gel electrophoresis. The results were as follows: Figure 8 .

[0135] e. Plasmid map: The results are as follows Fig. 9 .

[0136] d. Sequencing results: The sequencing primer was T7ter: TGCTAGTTATTGCTCAGCGG (SEQ ID NO.19), and the results were as follows Fig.10 .

[0137] 4.2 Expression identification, optimization and solubility analysis

[0138] a. Transform BL21(DE3) competent cells with plasmid pET-22b(+), invert and culture at 37℃ overnight. Select a single clone and culture in LB medium at 37℃ until the bacterial OD600 is 0.6-0.8, add IPTG to a final concentration of 0.5mM, culture at 37℃ for 4 hours, then centrifuge, collect the bacteria and prepare samples for SDS-PAGE and Western Blot analysis;

[0139] b. After the inoculated seed bacteria were cultured to a bacterial OD600 of 0.6-0.8, IPTG was added to the culture to a final concentration of 0.2 mM and 1 mM, respectively, and cultured at 37°C and 15°C at 220 rpm for 4 hours and 16 hours, respectively, to induce the expression of the fusion protein, and samples were prepared for SDS-PAGE analysis under each condition;

[0140] In the previous step, the bacterial suspensions of each condition were centrifuged to collect the bacteria, broken (Tris-NaCl buffer), and the supernatant precipitates were sampled and analyzed by SDS-PAGE.

[0141] 4.3 Amplification and purification

[0142] a. The optimal clone was cultured in LB medium at 37°C until OD 600 =0.6~0.8, induced at 15℃ for 16 hours and harvested;

[0143] b. Collect the bacteria by centrifugation, resuspend the bacteria, and disrupt them by ultrasonication;

[0144] c. Centrifuge and purify the supernatant by nickel column affinity chromatography. The buffer is as follows:

[0145] Equilibration buffer: "PBS-NaCl", pH 7.4

[0146] Washing buffer: "PBS-NaCl", pH 7.4 + 50 mM imidazole

[0147] Elution buffer: "PBS-NaCl", pH 7.4 + 500 mM imidazole

[0148] d. Prepare samples for SDS-PAGE analysis.

[0149] 4.4 Protein dialysis

[0150] The samples that meet the requirements were combined and dialyzed into PBS, pH 7.4, and then filtered for sterilization.

[0151] 4.5 Experimental Results

[0152] The results are as follows Figure 5-16 .

[0153] The results showed that the plasmid vector containing the single domain antibody gene sequence was successfully constructed. It is feasible to express single domain antibodies in prokaryotic systems, and sufficient amounts of high purity single domain antibodies can be purified from the supernatant after cell disruption.

[0154] Example 5 Expression of single domain antibodies in eukaryotic systems and purification thereof

[0155] 5.1 Cell transfection

[0156] The VHH-human Fc fusion protein plasmid was constructed, and the plasmid was transfected using CHO-S expression system transfection reagent, and the supernatant was collected for purification.

[0157] 5.2 Protein purification Mab Select Sure LX gravity column purification

[0158] a. After cell centrifugation, the culture supernatant was directly purified with Mab Select Sure LX. The filler was loaded into a gravity column tube with the following buffer:

[0159] Equilibration buffer: PBS pH 7.4

[0160] Washing buffer: PBS pH 7.4

[0161] Elution buffer: 0.1 M glycine, pH 3.5

[0162] b. Equilibrate with 20 column volumes of equilibration solution PBS, add the equilibrated filler to the culture medium supernatant, and incubate with rotation at 4°C for 1-1.5h;

[0163] c. Add the incubation product to the gravity column tube and collect the flow-through;

[0164] d. After loading, continue to wash with 20 times column volume of equilibrium buffer;

[0165] e. After the washing is completed, use elution buffer to elute and collect;

[0166] f. After elution, adjust the pH to neutral with 1M Tris-HCl, pH 7.4;

[0167] g. SDS-PAGE electrophoresis detection, ultrafiltration and exchange of liquid into PBS to determine the concentration and purity.

[0168] Example 6 ELISA to verify the ability of single domain antibodies to bind to different serotypes of AAV

[0169] 6.1 ELISA validation process

[0170] a. AAV2, AAV5, AAV6, and AAV8 were diluted with coating buffer and incubated at 4°C overnight;

[0171] b. Wash the plate 3 times with 200ul PBST (0.05% tween-20, pH 7.2);

[0172] c. Add 100ul / well 5% (v / v) skim milk powder and block at 37°C for 1 hour;

[0173] d. Wash the plate 3 times, add 100ul / well single domain antibody-human IgG Fc (2ug / ml) to the experimental group and 100ul / well to the blank control

[0174] PBS (pH 7.2), incubated at 37°C for 1 h;

[0175] e. Wash the plate three times, add 100ul / well anti-human IgG1 Fc antibody, and incubate at 37°C for 1 hour;

[0176] f. Wash the plate 3 times and add 100ul / well TMB for color development;

[0177] g. Add 100ul / well stop solution;

[0178] h. Measure the absorbance at 450nm using an enzyme-labeled instrument.

[0179] 6.2 The single domain antibody expressed in the eukaryotic system is fused with human IgG1 Fc. The following is the ELISA result

[0180] Table 1. OD450nm readings of single domain antibody and AAV2 ELISA binding activity verification

[0181]

[0182]

[0183] Table 2. OD450nm readings of single domain antibody and AAV5 ELISA binding activity verification

[0184] AAV5 vg / well Single domain antibodies Control group 1e+010 3.1272 0.2501 3.33e+009 2.4979 0.2931 1.11e+009 1.3628 0.2049 3.7e+008 0.6135 0.1537 1.23e+008 0.2569 0.0904

[0185] Table 3. OD450nm readings of single domain antibody and AAV6 ELISA binding activity verification

[0186] AAV6 vg / well Single domain antibodies Control group 1e+010 4 0.1649 3.33e+009 2.5534 0.1447 1.11e+009 1.4094 0.1469 3.7e+008 0.5703 0.1433 1.23e+008 0.2084 0.1296

[0187] Table 4 OD450nm readings of single domain antibody and AAV8 ELISA binding activity verification

[0188] AAV8 vg / well Single domain antibodies Control group 1e+010 4 0.0443 3.33e+009 2.0514 0.0512 1.11e+009 0.894 0.0472 3.7e+008 0.3211 0.05 1.23e+008 0.0842 0.0262

[0189] Combination Figure 16-19 As well as the above table, it can be seen that single-domain antibodies have strong binding ability with AAV2, AAV5, AAV6, and AAV8.

[0190] 6.3 Prokaryotic expression of single-domain antibodies and verification of their binding activity to AAV by ELISA, with the detection antibody being anti-single-domain antibody-HRP antibody

[0191] a. AAV2, AAV5, AAV6, and AAV8 were diluted with coating buffer and incubated at 4°C overnight;

[0192] b. Wash the plate 3 times with 200ul PBST (0.05% tween-20, pH 7.2);

[0193] c. Add 100ul / well 5% (v / v) skim milk powder and block at 37°C for 1 hour;

[0194] d. Wash the plate three times, add 100ul / well single domain antibody (2ug / ml) to the experimental group and 100ul / well PBS (pH7.2) to the blank control, and incubate at 37°C for 1 hour;

[0195] e. Wash the plate three times, add 100ul / well anti-single domain antibody-HRP (1:5000), and incubate at 37°C for 1 hour;

[0196] f. Wash the plate 3 times and add 100ul / well TMB for color development;

[0197] g. Add 100ul / well stop solution;

[0198] h. Measure the absorbance at 450nm using an enzyme-labeled instrument.

[0199] Table 5. OD450nm readings for single domain antibody and AAV2 ELISA binding activity verification

[0200]

[0201]

[0202] Table 6. OD450nm readings for single domain antibody and AAV5 ELISA binding activity verification

[0203] AAV5 vg / well Single domain antibodies Control group 1e+010 3.161299944 0.08114 3.33e+009 2.325000048 0.063 1.11e+009 1.286200047 0.0422 3.7e+008 0.546199977 0.0385 1.23e+008 0.243499994 0.0595

[0204] Table 7. OD450nm readings for single domain antibody and AAV6 ELISA binding activity verification

[0205] AAV6 vg / well Single domain antibodies Control group 1e+010 3.536999941 0.0431 3.33e+009 2.668100119 0.0469 1.11e+009 1.697700024 0.0444 3.7e+008 0.668600023 0.0418 1.23e+008 0.227500007 0.0514

[0206] Table 8. OD450nm readings for single domain antibody and AAV8 ELISA binding activity verification

[0207] AAV8 vg / well Single domain antibodies Control group 1e+010 2.9156 0.0583 3.33e+009 1.7639 0.0533 1.11e+009 0.7865 0.0484 3.7e+008 0.2412 0.0466 1.23e+008 0.1252 0.0321

[0208] Combination Figure 20-23 , from the ELISA results of single-domain antibodies expressed in eukaryotic systems fused with human IgG1 Fc, AAV2, AAV5, AAV6 and AAV8 can all have strong binding ability with single-domain antibodies. Next, we used anti-single-domain antibody-HRP antibody to detect the binding activity of single-domain antibodies with different serotypes of AAV, and the results showed that single-domain antibodies have good binding activity with AAV2, AAV5, AAV6 and AAV8.

[0209] Example 7 Purification test of AAV stock solution by purification filler coupled with anti-AAV single domain antibody

[0210] We also coupled single-domain antibodies to microspheres to construct AAV affinity purification fillers and tested their purification capabilities. The experimental steps and results of single-domain antibody affinity filler purification of AAV are as follows:

[0211] 7.1 Preparation of AAV samples

[0212] 7.1.1 Cultivation and transfection of packaging cell line 293T cells

[0213] a. Take 293T out of liquid nitrogen and place it in a 37°C water bath to dissolve it quickly;

[0214] b. Transfer the cell solution to a 15 mL centrifuge tube and add 1 mL of fresh complete medium. Mix by pipetting and centrifuge at 156 × g (1000 rpm) for 5 minutes. Discard the supernatant and add 1 mL of fresh complete medium to resuspend the cells.

[0215] c. Add the cell resuspension to a 100 mm culture dish. Add 9 mL of culture medium to each dish in advance. Mix well and place the dish in a 37°C, 5% CO2 incubator for culture.

[0216] 7.1.2 Adeno-associated virus packaging

[0217] a. Extract the adeno-associated virus shuttle plasmid and its auxiliary packaging plasmid respectively to high purity and endotoxin-free for use;

[0218] b. When the cell density is 70-90%, transfect 293T cells. The plasmid transfection system is as follows:

[0219]

[0220] c. Preheat DMEM (containing three antibodies) to 37°C, return the transfection reagent to room temperature, and mix the culture medium DMEM and pHelper evenly;

[0221] d. Add the reagent in the pHelper tube to the serotype centrifuge tube according to the amount required for each serotype, and then add the corresponding serotype plasmid amount and mix well;

[0222] e. Add the target plasmid and then the transfection reagent into the centrifuge tube and mix well with a pipette. Let it stand for 20 minutes and transfer it to a dish.

[0223] 7.1.3 Preparation of crude virus extract

[0224] a. Observe the fluorescence after transfection, add fresh culture medium once in the middle, digest the cells 72 hours after transfection, centrifuge at 3000rpm for 10 minutes, pour out the supernatant, add PBS to resuspend, and freeze-thaw the resuspended liquid three times in liquid nitrogen and 37℃ water bath, then centrifuge at 3000rpm for 10 minutes.

[0225] b. Take the supernatant, add 3 μL Benzonase enzyme (enzyme: PBS = 1:100), and incubate at 37°C for 1 hour to remove the cell genome and residual plasmid DNA in the virus solution;

[0226] c. Centrifuge at 3000 rpm and 4°C for 10 minutes. The titer of the AAV crude extract was measured and used in subsequent purification and verification experiments of single-domain antibody affinity microspheres.

[0227] 7.2 Purification of AAV using single domain antibody affinity purification media

[0228] a. 1 ml of single domain antibody affinity filler was loaded into the column, and the column was equilibrated with AAV binding buffer (PBS + 0.35 M NaCl + 0.01% F68, pH 7.2-7.4) on AKTA for 3-5 CV;

[0229] b. The prepared AAV crude extract (treated with universal enzyme, filtered through 0.45 μm after centrifugation, and 0.01% F68) was loaded at a flow rate of 0.8 ml / min;

[0230] c. After loading, wash with binding buffer until baseline equilibrium;

[0231] d. Elute with elution buffer (0.1 M glycine, pH 2.0 adjusted with hydrochloric acid, 0.01% F68, 2 mM magnesium chloride), and immediately add 1 M Tris at a ratio of 1:10 to neutralize the collected eluate;

[0232] e) Wash with elution buffer (0.1 M phosphoric acid + 0.01% F68) for 5CV, then wash with PBS (pH 7.2) for another 5CV, and finally rinse the single domain antibody with 20% ethanol and store it in 20% ethanol.

[0233] Table 11. Titers of each component detected by ddPCR after affinity purification of single domain antibody affinity medium for AAV2 dynamic load

[0234] AAV2 Titer Sample (VG) 5.72E+12 Eluent (VG) 5.19E+12 Recovery rate (%) 90.73

[0235] Table 12. Titers of each component detected by ddPCR after affinity purification of single domain antibody affinity medium for AAV5 dynamic load

[0236] AAV5 Titer Sample (VG) 3.36E+13 Eluent (VG) 2.63E+13 Recovery rate (%) 78.12

[0237] Table 13. Titers of each component detected by ddPCR after affinity purification of single domain antibody affinity medium for AAV8 dynamic load

[0238] AAV8 Titer Load crude extract (VG) 1.33E+13 Eluent (VG) 1.25E+13 Recovery rate (%) 93.67

[0239] Combination Figure 24-27 And Tables 11-13 show that agarose gel microspheres coupled with single domain antibodies can affinity purify adeno-associated viruses AAV2, AAV5, and AAV8, with recovery rates of 90.73%, 78.12%, and 93.67%, respectively.

[0240] Example 8 Mutant 1 amino acid sequence

[0241] Single domain antibody mutant 1 variable region sequence G30A (SEQ ID NO.20)

[0242] QVQLQESGGGLVQAGGSLRLSCAASGRTH A MYAMGWFRQAPGKEREFVAVQDLTASNTHYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMSGSYNSARDYDYWGQGTQVTVSS

[0243] The IMGT rule number

[0244] CDR1 sequence is GRTH A MYA (SEQ ID NO. 21)

[0245] The CDR2 sequence is QDLTASNT (SEQ ID NO. 22)

[0246] The CDR3 sequence is AAGPTIMSGSYNSARDYDY (SEQ ID NO. 23)

[0247] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 24)

[0248] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO. 25)

[0249] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO. 26)

[0250] FR4 sequence is WGQGTQVTVSS (SEQ ID NO. 27)

[0251] Example 9 Mutant 2 amino acid sequence

[0252] Single domain antibody mutant 2 variable region sequence S56T (SEQ ID NO.28)

[0253] QVQLQESGGGLVQAGGSLRLSCAASGRTHGMYAMGWFRQAPGKEREFVAVQDLTATNTHYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMSGSYNSARDYDYWGQGTQVTVSS

[0254] The IMGT rule number

[0255] The CDR1 sequence is GRTHGMYA (SEQ ID NO. 29)

[0256] CDR2 sequence is QDLTATNT (SEQ ID NO.30)

[0257] The CDR3 sequence is AAGPTIMSGSYNSARDYDY (SEQ ID NO. 31)

[0258] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 32)

[0259] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO. 33)

[0260] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO. 34)

[0261] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.35)

[0262] Example 10 Mutant 3 amino acid sequence

[0263] Single domain antibody mutant 3 variable region sequence G105A (SEQ ID NO.36)

[0264] QVQLQESGGGLVQAGGSLRLSCAASGRTHGMYAMGWFRQAPGKEREFVAVQDLTASNTHYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMS A SYNSARDYDYWGQGTQVTVSS

[0265] The IMGT rule number

[0266] The CDR1 sequence is GRTHGMYA (SEQ ID NO. 37)

[0267] The CDR2 sequence is QDLTASNT (SEQ ID NO. 38)

[0268] CDR3 sequence is AAGPTIMS A SYNSARDYDY (SEQ ID NO. 39)

[0269] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 40)

[0270] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO.41)

[0271] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO. 42)

[0272] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.43)

[0273] Example 11 Mutant 4 amino acid sequence

[0274] Single domain antibody mutant 4 variable region sequence G30A / S56T / G105A (SEQ ID NO.44)

[0275] QVQLQESGGGLVQAGGSLRLSCAASGRTH A MYAMGWFRQAPGKEREFVAVQDLTATNTHYSSAVKGRFTISRDNALNTAYLQMNNLKPEDTAVYYCAAGPTIMS A SYNSARDYDYWGQGTQVTVSS

[0276] The IMGT rule number

[0277] CDR1 sequence is GRTH A MYA (SEQ ID NO.45)

[0278] CDR2 sequence is QDLTATNT (SEQ ID NO.46)

[0279] CDR3 sequence is AAGPTIMS A SYNSARDYDY (SEQ ID NO. 47)

[0280] FR1 sequence is QVQLQESCGCLVGAGGSLRLSCAS (SEQ ID NO. 48)

[0281] FR2 sequence is MGWFRGAPGKEREFVAV (SEQ ID NO. 49)

[0282] FR3 sequence is HYSSAVKGRFTISRDNAKNTAYLIANLXPEDTAVYYC (SEQ ID NO.50)

[0283] FR4 sequence is WGQGTQVTVSS (SEQ ID NO.51)

[0284] Example 12 Ability of mutants 1-4 to bind to different serotypes of AAV

[0285] In order to verify the ability of different mutants to bind to different serotypes of AAV, we constructed and expressed the above mutants 1-4, and conducted the same experiment as the single domain antibody in Example 1, with the same operation method as described above. The specific results are as follows:

[0286] The quality inspection SDS-PAGE electrophoresis results after single domain antibody purification are as follows Figure 5-10 As shown:

[0287] Fig.28 . SDS-PAGE results of G30A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0288] Fig.29 . SDS-PAGE results of S56T protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0289] Fig.30 . SDS-PAGE results of G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0290] Fig.31 . SDS-PAGE results of G30A / S56T / G105A protein purification. Lane M: protein marker; Lane 1: reduced sample; Lane 2: non-reduced sample.

[0291] It can be seen that all mutants were successfully expressed.

[0292] The results of ELISA experiments on the ability of single domain antibody mutants to bind to different serotypes of AAV are shown in the following figure and table:

[0293] Fig.32. Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV2 ELISA.

[0294] Fig.33 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV5 ELISA.

[0295] Fig.34 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV6 ELISA.

[0296] Fig.35 . Analysis curve of the binding activity of single domain antibody wild type and its mutants to AAV8 ELISA.

[0297] Table 14. OD450nm readings of single domain antibody wild type and its mutants and AAV2 ELISA binding activity verification

[0298]

[0299] Table 15. OD450nm readings of single domain antibody wild type and its mutants and AAV5 ELISA binding activity verification

[0300]

[0301] Table 16. OD450nm readings of single domain antibody wild type and its mutants and AAV6 ELISA binding activity verification

[0302]

[0303] Table 17. OD450nm readings of single domain antibody wild type and its mutants and AAV8 ELISA binding activity verification

[0304]

[0305] According to the results of ELISA, the single-domain antibodies and their mutants showed considerable activity in binding to AAV2, AAV5, and AAV6.

[0306] In this specification, the schematic representation of the terms does not necessarily refer to the same embodiment. Moreover, the specific features, structures, materials or characteristics described can be combined in any suitable manner in one or more embodiments.

[0307] Based on the above ideal embodiments of the present invention, the relevant staff can make various changes and modifications without departing from the technical concept of the present invention through the above description. The technical scope of the present invention is not limited to the contents of the specification, and its technical scope must be determined according to the scope of the claims.

Claims

1. An adeno-associated virus affinity purification spin column, characterized in that: The invention comprises a sample inner tube (1) and a filtrate collecting tube (2) sleeved on the outside of the sample inner tube (1); an affinity filler filling section (3) is provided at the lower part of the sample inner tube (1); an upper layer filtering device (4) is provided on the upper side of the affinity filler filling section (3), and a lower layer filtering device (5) is provided on the lower side; the affinity filler contains a single domain antibody, and the single domain antibody comprises CDR1, CDR2, and CDR3. The amino acid sequence of the CDR1 is as shown in SEQ ID NO: 2, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity; The amino acid sequence of the CDR2 is as shown in SEQ ID NO: 3, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity; The amino acid sequence of the CDR3 is shown in SEQ ID NO: 4, or a mutant having 1-2 amino acid mutations and having at least 80%, 85%, 90%, 95% functional identity.

2. The adeno-associated virus affinity purification spin column according to claim 1, characterized in that The upper filter device (4) comprises an upper clamp ring (41), an upper filter disc (42) and an upper mesh plastic gasket (43) which are arranged in sequence from top to bottom; the lower filter device (5) comprises a lower clamp ring (51), a lower filter disc (52) and a lower mesh plastic gasket (53) which are arranged in sequence from top to bottom.

3. The adeno-associated virus affinity purification spin column according to claim 2, characterized in that: The pore size of the filter pores of the upper filter (42) is approximately 0.3-0.8 microns; the pore size of the filter pores of the lower filter (52) is approximately 0.3-0.8 microns.

4. The adeno-associated virus affinity purification spin column according to claim 1, characterized in that: The bottom of the sample inner tube (1) is provided with a liquid outlet (6), and the upper part of the sample inner tube (1) is provided with a clamping portion (7) for clamping with the filtrate collection tube (2), and the outer diameter of the clamping portion (7) is the same as the inner diameter of the filtrate collection tube (2).

5. The adeno-associated virus affinity purification spin column according to claim 4, characterized in that: The top of the sample inner tube (1) is connected to a leakproof cover (8) for sealing the sample inner tube (1), and the leakproof cover (8) comprises a connecting portion (81) connected to the sample inner tube (1), an opening and closing portion (82) for opening or closing the cover body, and a sealing portion (83) for plugging the sample inner tube (1) to prevent the sample from flowing out during centrifugation; the sealing portion (83) is a columnar structure, and the outer diameter of the sealing portion (83) matches the inner diameter of the upper portion of the sample inner tube (1).

6. The adeno-associated virus affinity purification spin column according to claim 4, characterized in that: The top outer ring of the filtrate collecting tube (2) is provided with a threaded opening (9), and the threaded opening (9) is connected to a threaded cover (10).

7. The adeno-associated virus affinity purification spin column according to claim 1, characterized in that: The single domain antibody also includes any one or more of the following technical features: a. The single-domain antibody further comprises a framework region FR1 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO: 5; b. The single domain antibody further comprises a framework region FR2 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO: 6; c. The single domain antibody further comprises a framework region FR3 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO: 7; d. The single domain antibody further comprises a framework region FR4 having at least 80%, 85%, 90%, or 95% identity to SEQ ID NO:

8.

8. The adeno-associated virus affinity purification spin column according to claim 1, characterized in that: The amino acid sequence of the single domain antibody is shown in SEQ ID NO.

1.

9. The adeno-associated virus affinity purification spin column according to claim 1, characterized in that: The single domain antibody further comprises any one of the following technical features: a. The amino acid sequence of the CDR1 is shown in SEQ ID NO: 21; b. The amino acid sequence of the CDR2 is shown in SEQ ID NO: 30; c. The amino acid sequence of the CDR3 is shown in SEQ ID NO: 39; d. The amino acid sequence of the CDR1 is shown in SEQ ID NO:45, the amino acid sequence of the CDR1 is shown in SEQ ID NO:46; the amino acid sequence of the CDR1 is shown in SEQ ID NO:47.

Citation Information

Cited By

  • Nanometer antibody specifically binding to AAV8 and application thereof

    CN120590517A

  • Nanobodies specifically binding aav8 and uses thereof

    CN120590517B